About GI Dynamics
GI Dynamics is pioneering a platform of technologies that affect key metabolic pathways resulting in gastric bypass-like resolution of type 2 diabetes and significant weight loss.
GI Dynamics is a highly innovative and rapidly expanding medical device company in the Boston area. The company was founded in 2003, and has raised $46 million in three rounds from top-tier venture capital companies including Advanced Technology Ventures, Cutlass Capital, Domain Associates, Johnson & Johnson Development Corporation and Polaris Venture Partners. GI Dynamics has also assembled a world class group of advisors with specialties in bariatric surgery, gastroenterology, endocrinology and medical weight loss.
The company holds significant IP to protect and preserve its platform technologies across global markets. GI Dynamics has ISO certification and its EndoBarrierTM -- a promising, breakthrough treatment for type 2 diabetes and obesity -- holds European CE Mark approval and ISO certification.
The EndoBarrier fits within a new class of treatment options between pharmaceutical regimens and surgery called nonsurgical therapeutics. Nonsurgical therapeutics are designed to address the limitations associated with pharmaceutical approaches and surgical options, and hold the potential to improve the patient's overall health by providing the control necessary to institute lifestyle and nutritional improvements to maintain therapeutic effect.
The EndoBarrier is commercially available in Europe and is currently considered an investigational device in the U.S.
The EndoBarrier is well-poised to become the cornerstone of a highly individualized type 2 diabetes and obesity patient care program.